抗生素合作與授權協議（2016-2026 年）

抗生素交易的權威基準

抗生素抗藥性日益嚴峻，抗生素合作夥伴關係也隨之形成，其交易結構反映了抗感染疾病療法開發中獨特的科學、監管和商業性動態。

本報告對 140 多項與抗生素相關的合作關係和許可協議進行了全面系統的分析，清楚地展示了夥伴關係在整個市場中的設計、談判和執行方式，並以證據為基礎進行了闡述。

充分了解市場標準。

本報告將使您準確了解抗生素相關交易的實際結構，使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑和忠誠度結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以清楚地了解合約條款如何根據開發階段、作用機制和合作夥伴情況而有​​所不同。
• 支持基於證據的評估和合約結構確定。
• 內部討論應基於實際交易數據，而非假設。
• 了解大型公司如何處理交易
• 在具有重要科學意義和獨特經濟意義的治療領域中，可視化合作夥伴的行為和重複交易模式。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，從而可以詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解抗生素夥伴關係中價值、風險和控制權的分配至關重要，尤其是在公共衛生優先事項和非常規商業模式產生影響的領域。
• 專為實際業務發展和策略制定而設計。

本報告廣泛用於以下用途：

• 感染疾病物販運的結構化和基準分析
• 在清晰的市場環境下準備談判
• 合作機會及目的地評估
• 支持以可靠證據為基礎的數據驅動型內部策略。
• 內容
• 超過 140 項與抗生素相關的合作和許可協議。
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 一個可全文搜尋的合約目錄（依公司、作用機制及開發階段分類）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 交易趨勢分析、關鍵交易案例分析和活躍交易相關人員分析。
• 關於抗生素產業交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易報告和合約層面的深入分析，為如何在抗生素領域建立、談判和評估夥伴關係提供了可靠的、基於證據的指導。

目錄

執行摘要

第1章：引言

第2章：抗生素貿易趨勢

• 介紹
• 長期抗生素貿易
• 最活躍的抗生素相關人員
• 與抗生素相關的交易（按交易類型）
• 與抗生素相關的交易（按治療領域分類）
• 抗生素交易（按行業分類）
• 與抗生素相關的貿易條款與條件

第3章 主要抗生素貿易

• 介紹
• 與抗生素相關的交易（按價格）

第4章：抗生素交易中最活躍的相關人員

• 介紹
• 最活躍的抗生素相關人員
• 與最活躍的抗生素交易相關的公司簡介

第5章：抗生素合約談判指南

• 介紹
• 抗生素合約交易目錄

第6章：依技術類型分類的抗生素交易

• 交易清單
• 交易清單 - 抗生素相關交易（依公司分類）
• 交易清單 - 抗生素相關交易（按交易類型）
• 交易清單 - 抗生素相關交易（依治療領域分類）
• 交易類型的定義
• 關於這家研究公司
• 當前夥伴關係
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for antibiotic dealmaking

Antibiotic partnering is shaped by the growing challenge of antimicrobial resistance, with deal structures reflecting the unique scientific, regulatory, and commercial dynamics of developing anti-infective therapies.

This report provides a comprehensive and structured analysis of 140+ antibiotic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how antibiotic deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by development stage, mechanism of action, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a scientifically critical and economically distinct therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within antibiotic partnerships, particularly in areas influenced by public health priorities and non-traditional commercial models.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark anti-infective transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 140+ antibiotic collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, mechanism, and development stage)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for antibiotic dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how antibiotic partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotic dealmaking

• 2.1. Introduction
• 2.2. Antibiotic deals over the years
• 2.3. Most active antibiotic dealmakers
• 2.4. Antibiotic deals by deal type
• 2.5. Antibiotic deals by therapy area
• 2.6. Antibiotic deals by industry sector
• 2.7. Deal terms for antibiotic deals
  • 2.7.1 Antibiotic deals headline values
  • 2.7.2 Antibiotic deal upfront payments
  • 2.7.3 Antibiotic deal milestone payments
  • 2.7.4 Antibiotic royalty rates

Chapter 3 - Leading antibiotic deals

• 3.1. Introduction
• 3.2. Top antibiotic deals by value

Chapter 4 - Most active antibiotic dealmakers

• 4.1. Introduction
• 4.2. Most active antibiotic dealmakers
• 4.3. Most active antibiotic deals company profiles

Chapter 5 - Antibiotic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Antibiotic contracts dealmaking directory

Chapter 6 - Antibiotic dealmaking by technology type

• Deal directory
• Deal directory - Antibiotic deals by company A-Z
• Deal directory - Antibiotic deals by deal type
• Deal directory - Antibiotic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Antibiotic deals since 2016
• Figure 2: Active antibiotic dealmaking activity since 2016
• Figure 3: Antibiotic deals by deal type since 2016
• Figure 4: Antibiotic deals by therapy area since 2016
• Figure 5: Antibiotic deals by industry sector since 2016
• Figure 6: Antibiotic deals with a headline value
• Figure 7: Antibiotic deals with an upfront value
• Figure 8: Antibiotic deals with a milestone value
• Figure 9: Antibiotic deals with a royalty rate value
• Figure 10: Top antibiotic deals by value since 2016
• Figure 11: Most active antibiotic dealmakers since 2016
• Figure 12: Antibiotic deals by technology type since 2016